| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1644 | 2015 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 1541 | 2019 |
| Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives J Mazières, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ... Journal of clinical oncology 31 (16), 1997-2003, 2013 | 737 | 2013 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 542 | 2018 |
| Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN … JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet Oncology 22 (1), 51-65, 2021 | 436 | 2021 |
| Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study R Corre, L Greillier, H Le Caër, C Audigier-Valette, N Baize, H Bérard, ... J Clin Oncol 34 (13), 1476-1483, 2016 | 386 | 2016 |
| Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease L Savale, A Chaouat, S Bastuji-Garin, E Marcos, L Boyer, B Maitre, ... American journal of respiratory and critical care medicine 179 (7), 566-571, 2009 | 368 | 2009 |
| Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction … M Pérol, C Chouaid, D Pérol, F Barlési, R Gervais, V Westeel, J Crequit, ... Journal of Clinical Oncology 30 (28), 3516-3524, 2012 | 287 | 2012 |
| Role for interleukin-6 in COPD-related pulmonary hypertension A Chaouat, L Savale, C Chouaid, L Tu, B Sztrymf, M Canuet, B Maitre, ... Chest 136 (3), 678-687, 2009 | 276 | 2009 |
| Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study A Tison, G Quéré, L Misery, E Funck‐Brentano, FX Danlos, E Routier, ... Arthritis & rheumatology 71 (12), 2100-2111, 2019 | 245 | 2019 |
| Bevacizumab in patients with nonsquamous non–small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study B Besse, S Le Moulec, J Mazières, H Senellart, F Barlesi, C Chouaid, ... Clinical Cancer Research 21 (8), 1896-1903, 2015 | 245 | 2015 |
| Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the … F Barlesi, A Scherpereel, V Gorbunova, R Gervais, A Vikström, C Chouaid, ... Annals of oncology 25 (5), 1044-1052, 2014 | 215 | 2014 |
| Efficacy and safety of anti–PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018 F Guisier, C Dubos-Arvis, F Viñas, H Doubre, C Ricordel, S Ropert, ... Journal of Thoracic Oncology 15 (4), 628-636, 2020 | 210 | 2020 |
| TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo … E Quoix, H Lena, G Losonczy, F Forget, C Chouaid, Z Papai, R Gervais, ... The Lancet Oncology 17 (2), 212-223, 2016 | 209 | 2016 |
| Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review K Atsou, C Chouaid, G Hejblum BMC medicine 9, 1-16, 2011 | 201 | 2011 |
| Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01) C Chouaid, C Dujon, P Do, I Monnet, A Madroszyk, H Le Caer, JB Auliac, ... Lung cancer 86 (2), 170-173, 2014 | 182 | 2014 |
| Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease H Noureddine, G Gary-Bobo, M Alifano, E Marcos, M Saker, N Vienney, ... Circulation research 109 (5), 543-553, 2011 | 175 | 2011 |
| Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS MC Meyohas, P Roux, D Bollens, C Chouaid, W Rozenbaum, JL Meynard, ... Clinical infectious diseases 21 (3), 628-633, 1995 | 167 | 1995 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 163 | 2016 |
| The association between asthma control, health care costs, and quality of life in France and Spain M Doz, C Chouaid, L Com-Ruelle, E Calvo, M Brosa, J Robert, ... BMC pulmonary medicine 13, 1-10, 2013 | 162 | 2013 |
